Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

ClinicalTrials.gov ID: NCT03884101

Public ClinicalTrials.gov record NCT03884101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Study identification

NCT ID
NCT03884101
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
842 participants

Conditions and interventions

Interventions

  • Carboplatin Drug
  • Lenvatinib Drug
  • Paclitaxel Drug
  • Pembrolizumab Biological

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 10, 2019
Primary completion
Oct 1, 2023
Completion
Feb 4, 2025
Last update posted
Feb 1, 2026

2019 – 2025

United States locations

U.S. sites
29
U.S. states
18
U.S. cities
27
Facility City State ZIP Site status
University of South Alabama, Mitchell Cancer Institute ( Site 0245) Mobile Alabama 36604
Arizona Oncology Associates PC- HOPE ( Site 8005) Tucson Arizona 85711
UCLA Hematology and Oncology Clinic (Westwood) ( Site 0233) Los Angeles California 90095
University of Colorado Cancer Center ( Site 0204) Aurora Colorado 80045
Smilow Cancer Hospital at Yale New Haven ( Site 0202) New Haven Connecticut 06511
University of Miami Health System ( Site 0249) Miami Florida 33136
Georgia Cancer Center at Augusta University ( Site 0222) Augusta Georgia 30912
Women's Cancer Care ( Site 0208) Covington Louisiana 70433
Maine Medical Partners ( Site 0217) Scarborough Maine 04074
Minnesota Oncology Hematology, PA ( Site 8003) Minneapolis Minnesota 55404
Memorial Sloan-Kettering Cancer Center At Basking Ridge ( Site 0268) Basking Ridge New Jersey 07920
John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0226) Hackensack New Jersey 07601
Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0273) Middletown New Jersey 07748
MSKCC-Bergen ( Site 0276) Montvale New Jersey 07645
Holy Name Medical Center ( Site 0235) Teaneck New Jersey 07666
Memorial Sloan-Kettering Cancer Center at Commack ( Site 0267) Commack New York 11725
Memorial Sloan Kettering Cancer Center - West Harrison ( Site 0274) Harrison New York 10604
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0206) New York New York 10011
Memorial Sloan Kettering Cancer Center ( Site 0246) New York New York 10022
University of Rochester ( Site 0238) Rochester New York 14642
Memorial Sloan Kettering Cancer Center - Nassau ( Site 0275) Uniondale New York 11553
University of North Carolina- Chapel Hill ( Site 0254) Chapel Hill North Carolina 27599
Roger Maris Cancer Center ( Site 0277) Fargo North Dakota 58102
Willamette Valley Cancer Institute and Research Center ( Site 8004) Eugene Oregon 97401
Sanford Cancer Center Oncology Clinic ( Site 0205) Sioux Falls South Dakota 57104
Parkland Health & Hospital System ( Site 0272) Dallas Texas 75235
University of Texas Southwestern Medical Center ( Site 0264) Dallas Texas 75390-9015
Texas Oncology-The Woodlands ( Site 8000) The Woodlands Texas 77380
Legacy Salmon Creek Medical Center ( Site 0253) Vancouver Washington 98686

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 166 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03884101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 1, 2026 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03884101 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →